Bioinformatics analysis of gene expression profiles in hepatocellular carcinoma

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 11, 2015, Pages 2054-2061

  Shangguan, H ^a   Tan, S Y ^a   Zhang, J R ^a,b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Bioinformatics; Expression profile; Hepatocellular carcinoma; Key gene

Indexed keywords

ARTICLE; BIOINFORMATICS; COMPUTER PROGRAM; CONTROLLED STUDY; GENE EXPRESSION; GENE ONTOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; ONCOGENE; PROTEIN PROTEIN INTERACTION; BIOLOGY; GENE EXPRESSION PROFILING; GENETICS; LIVER TUMOR; PROCEDURES; TUMOR GENE;

TRANSCRIPTOME;

CARCINOMA, HEPATOCELLULAR; COMPUTATIONAL BIOLOGY; GENE EXPRESSION PROFILING; GENE ONTOLOGY; GENES, NEOPLASM; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; PROTEIN INTERACTION MAPS; SOFTWARE; TRANSCRIPTOME;

EID: 84942235878     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. JEMAL A, BRAY F, CENTER MM, FERLAY J, WARD E, FORMAN D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. SIMON R, LAM A, LI MC, NGAN M, MENENZES S, ZHAO Y. Analysis of gene expression data using BRBArrayTools. Cancer Inform 2007; 3: 11-17.
3. FRANCESCHINI A, SZKLARCZYK D, FRANKILD S, KUHN M, SIMONOVIC M, ROTH A, LIN J, MINGUEZ P, BORK P, VON MERING C, JENSEN LJ. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 2013; 41: D808-15.
4. SAITO R, SMOOT ME, ONO K, RUSCHEINSKI J, WANG PL, LOTIA S, PICO AR, BADER GD, IDEKER T. A travel guide to Cytoscape plugins. Nat Methods 2012; 9: 1069-1076.
5. SCARDONI G, PETTERLINI M, LAUDANNA C. Analyzing biological network parameters with CentiScaPe. Bioinformatics 2009; 25: 2857-2859.
6. AN O, PENDINO V, D'ANTONIO M, RATTI E, GENTILINI M, CICCARELLI FD. NCG 4.0: the network of cancer genes in the era of massive mutational screenings of cancer genomes. Database (Oxford) 2014; 2014: bau015.
7. PEREIRA F, BARBACHANO A, SILVA J, BONILLA F, CAMPBELL MJ, MUNOZ A, LARRIBA MJ. KDM6B/JMJD3 histone demethylase is induced by vitamin D and modulates its effects in colon cancer cells. Hum Mol Genet 2011; 20: 4655-4665.
8. HAN S, LI T, ELLIS E, STROM S, CHIANG JY. A novel bile acid-activated vitamin D receptor signaling in human hepatocytes. Mol Endocrinol 2010; 24: 1151-1164.
9. OHTA M, TATEISHI K, KANAI F, WATABE H, KONDO S, GULENG B, TANAKA Y, ASAOKA Y, JAZAG A, IMAMURA J, IJICHI H, IKENOUE T, SATA M, MIYAGISHI M, TAIRA K, TADA M, KAWABE T, OMATA M. p53-Independent negative regulation of p21/cyclin-dependent kinase-interacting protein 1 by the Sonic hedgehogglioma-associated oncogene 1 pathway in gastric carcinoma cells. Cancer Res 2005; 65: 10822-10829.
10. THAYER SP, DI MAGLIANO MP, HEISER PW, NIELSEN CM, ROBERTS DJ, LAUWERS GY, QI YP, GYSIN S, FERNÁNDEZDEL CASTILLO C, YAJNIK V, ANTONIU B, MCMAHON M, WARSHAW AL, HEBROK M. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003; 425: 851-856.
11. PATIL MA, ZHANG J, HO C, CHEUNG ST, FAN ST, CHEN X. Hedgehog signaling in human hepatocellular carcinoma. Cancer Biol Ther 2006; 5: 111-117.
12. HUANG S, HE J, ZHANG X, BIAN Y, YANG L, XIE G, ZHANG K, TANG W, STELTER AA, WANG Q, ZHANG H, XIE J. Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis 2006; 27: 1334-1340.
13. BERMAN DM, KARHADKAR SS, MAITRA A, MONTES DE OCA R, GERSTENBLITH MR, BRIGGS K, PARKER AR, SHIMADA Y, ESHLEMAN JR, WATKINS DN, BEACHY PA. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003; 425: 846-851.
14. YUAN RH, JENG YM, CHEN HL, LAI PL, PAN HW, HSIEH FJ, LIN CY, LEE PH, HSU HC. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol 2006; 209: 549-558.
15. LI C, TAN YX, ZHOU H, DING SJ, LI SJ, MA DJ, MAN XB, HONG Y, ZHANG L, LI L, XIA QC, WU JR, WANG HY, ZENG R. Proteomic analysis of hepatitis B virus-associated hepatocellular carcinoma: Identification of potential tumor markers. Proteomics 2005; 5: 1125-1139.
16. CHEN Y, LIN MC, YAO H, WANG H, ZHANG AQ, YU J, HUI CK, LAU GK, HE ML, SUNG J, KUNG HF. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology 2007; 46: 200-208.
17. SINGER S, EHEMANN V, BRAUCKHOFF A, KEITH M, VREDEN S, SCHIRMACHER P, BREUHAHN K. Protumorigenic overexpression of stathmin/Op18 by gain-offunction mutation in p53 in human hepatocarcinogenesis. Hepatology 2007; 46: 759-768.
18. CHEN G, WANG H, GHARIB TG, HUANG CC, THOMAS DG, SHEDDEN KA, KUICK R, TAYLOR JM, KARDIA SL, MISEK DE, GIORDANO TJ, IANNETTONI MD, ORRINGER MB, HANASH SM, BEER DG. Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas. Mol Cell Proteomics 2003; 2: 107-116.
19. KOUZU Y, UZAWA K, KOIKE H, SAITO K, NAKASHIMA D, HIGO M, ENDO Y, KASAMATSU A, SHIIBA M, BUKAWA H, YOKOE H, TANZAWA H. Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer 2006; 94: 717-723.
20. KARST AM, LEVANON K, DURAISAMY S, LIU JF, HIRSCH MS, HECHT JL, DRAPKIN R. Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol Oncol 2011; 123: 5-12.
21. TRINEI M, LANFRANCONE L, CAMPO E, PULFORD K, MASON DY, PELICCI PG, FALINI B. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Res 2000; 60: 793-798.
22. HAZRA A, FUCHS CS, KAWASAKI T, KIRKNER GJ, HUNTER DJ, OGINO S. Germline polymorphisms in the onecarbon metabolism pathway and DNA methylation in colorectal cancer. Cancer Causes Control 2010; 21: 331-345.
23. GOODE EL, CHENEVIX-TRENCH G, HARTMANN LC, FRIDLEY BL, KALLI KR, VIERKANT RA, LARSON MC, WHITE KL, KEENEY GL, OBERG TN, CUNNINGHAM JM, BEESLEY J, JOHNATTY SE, CHEN X, GOODMAN KE, ARMASU SM, RIDER DN, SICOTTE H, SCHMIDT MM, ELLIOTT EA, HØGDALL E, KJÆR SK, FASCHING PA, EKICI AB, LAMBRECHTS D, DESPIERRE E, HØGDALL C, LUNDVALL L, KARLAN BY, GROSS J, BROWN R, CHIEN J, DUGGAN DJ, TSAI YY, PHELAN CM, KELEMEN LE, PEETHAMBARAM PP, SCHILDKRAUT JM, SHRIDHAR V, SUTPHEN R, COUCH FJ, SELLERS TA; OVARIAN CANCER ASSOCIATION CONSORTIUM. Assessment of hepatocyte growth factor in ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev 2011; 20: 1638-1648.
24. HU Z, ZHOU Z, XIONG G, WANG Y, LAI Y, DENG L, YANG J. Cyclin D1 G870A polymorphism and the risk of hepatocellular carcinoma in a Chinese population. Tumour Biol 2014; 35: 5607-5612.
25. INTHAL A, ZEITLHOFER P, ZEGINIGG M, MORAK M, GRAUSENBURGER R, FRONKOVA E, FAHRNER B, MANN G, HAAS OA, PANZER-GRÜMAYER R. CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia. Leukemia 2012; 26: 1797-1803.
26. LOVE C, SUN Z, JIMA D, LI G, ZHANG J, MILES R, RICHARDS KL, DUNPHY CH, CHOI WW, SRIVASTAVA G, LUGAR PL, RIZZIERI DA, LAGOO AS, BERNAL-MIZRACHI L, MANN KP, FLOWERS CR, NARESH KN, EVENS AM, CHADBURN A, GORDON LI, CZADER MB, GILL JI, HSI ED, GREENOUGH A, MOFFITT AB, MCKINNEY M, BANERJEE A, GRUBOR V, LEVY S, DUNSON DB, DAVE SS. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012; 44: 1321-1325.
27. GUICHARD C, AMADDEO G, IMBEAUD S, LADEIRO Y, PELLETIER L, MAAD IB, CALDERARO J, BIOULAC-SAGE P, LETEXIER M, DEGOS F, CLÉMENT B, BALABAUD C, CHEVET E, LAURENT A, COUCHY G, LETOUZÉ E, CALVO F, ZUCMAN-ROSSI J. Integrated analysis of somat ic mutat ions and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012; 44: 694-698.
28. HUANG J, DENG Q, WANG Q, LI KY, DAI JH, LI N, ZHU ZD, ZHOU B, LIU XY, LIU RF, FEI QL, CHEN H, CAI B, ZHOU B, XIAO HS, QIN LX, HAN ZG. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet 2012; 44: 1117-1121.
29. LI M, ZHAO H, ZHANG X, WOOD LD, ANDERS RA, CHOTI MA, PAWLIK TM, DANIEL HD, KANNANGAI R, OFFERHAUS GJ, VELCULESCU VE, WANG L, ZHOU S, VOGELSTEIN B, HRUBAN RH, PAPADOPOULOS N, CAI J, TORBENSON MS, KINZLER KW. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet 2011; 43: 828-829.
30. JIN B, WANG W, DU G, HUANG GZ, HAN LT, TANG ZY, FAN DG, LI J, ZHANG SZ. Identifying hub genes and dysregulated pathways in hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 2015; 9: 592-601.